Incyte
INCY
113.44
+0.71
+0.63%
Incyte
US · INCY
#803 by market cap
Listed 1970
113.44
+0.71
+0.63%
Live - 5344 symbols - heartbeat 219s ago
· 2026-10-08 07:46
Pre-market
113.00
-0.39%
After-hours
111.97
-1.30%
Overnight
113.45
+0.01%
- Market cap
- 22.99B
- P/E (TTM)i
- 14.45
- P/Bi
- 3.62
- EPSi
- 6.41
- Div yieldi
- 0.00%
- 52W posi
- 62%
Reader sentiment
Are you bullish or bearish on INCY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.0 percentage points.
Institutional ownership
- Held by institutions
- 102.30% -1.00pp
- Institutions
- 1,093 -5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund69.56%
Hedge Fund23.83%
Government Pension Fund3.48%
Public Company2.59%
Private Company1.29%
Sovereign Wealth Fund0.67%
Individual/Insider0.47%
VC/PE Fund0.21%
Family Office/Trust0.21%
Top holders as of 2026-06-30
Baker Bros. Advisors LP
15.18% · 30.76M sh
BlackRock
8.90% · 18.03M sh
Vanguard Capital Management, LLC
5.90% · 11.97M sh
Dodge & Cox
5.90% · 11.96M sh
State Street Global Advisors
4.80% · 9.72M sh
Vanguard Portfolio Management, LLC
3.84% · 7.79M sh
AQR Capital Management
2.56% · 5.18M sh
Geode Capital Management, LLC
2.34% · 4.75M sh
LSV Asset Management
2.03% · 4.12M sh
Wellington Management Group
1.76% · 3.58M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 33 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Baker Bros. Advisors LP | -- | 15.18% |
| Julian Baker | Lead Independent Director | 0.14% |
| Herve Hoppenot | Chairperson & CEO | 0.04% |
| Paula Swain | Officer | 0.03% |
| Christiana Stamoulis | Chief Financial Officer | 0.03% |
| Paul Clancy | Independent Director | 0.01% |
| Jean-Jacques Bienaime | Independent Director | 0.01% |
| Edmund Harrigan | Independent Director | 0.01% |
| Jacqualyn Fouse | Independent Director | 0.01% |
| David Gardner | Chief Strategy Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Lee Heeson | Executive VP & Head of Incyte International | Sale to Issuer | -463 | $117.14 |
| 2026-09-29 | Edmund Harrigan | Independent Director | Other Acquisition | +206 | $121.35 |
| 2026-09-29 | Baker Bros. Advisors LP | -- | Other Acquisition | +644 | -- |
| 2026-09-29 | Paul Clancy | Independent Director | Other Acquisition | +203 | $121.35 |
| 2026-09-21 | David Gardner | Chief Strategy Officer | Sale to Issuer | -920 | $126.93 |
| 2026-09-14 | Pablo Cagnoni | President and Head of Research & Development | Derivative Exercise and Sale | -23,218 | $61.18–120.50 |
| 2026-08-24 | Soni Basi | Executive Vice President | Sale to Issuer | -504 | $129.72 |
| 2026-08-18 | Pablo Cagnoni | President and Head of Research & Development | Open Market Disposition | -10,801 | $125.56 |
| 2026-08-11 | Pablo Cagnoni | President and Head of Research & Development | Open Market Disposition | -10,803 | $120.04 |
| 2026-08-04 | Pablo Cagnoni | President and Head of Research & Development | Open Market Disposition | -10,640 | $122.69 |
| 2026-08-04 | Patrick Mayes | Vice President of Biotherapeutic Research | Derivative Exercise and Sale | -2,207 | $106.47–123.99 |
| 2026-08-02 | Patrick Mayes | Vice President of Biotherapeutic Research | Derivative Exercise and Sale | -45,767 | $61.18–122.19 |
| 2026-07-30 | Pablo Cagnoni | President and Head of Research & Development | Open Market Disposition | -15,888 | $119.70 |
| 2026-07-30 | Patrick Mayes | Vice President of Biotherapeutic Research | Open Market Disposition | -2,187 | $119.41 |
| 2026-07-22 | Michael Morrissey | Executive VP & Head of Global Technical Operations | Other Derivative Acquisition | +6,426 | $116.69 |
| 2026-07-22 | Michael Morrissey | Executive VP & Head of Global Technical Operations | Other Derivative Acquisition | +8,999 | -- |
| 2026-07-22 | Lee Heeson | Executive VP & Head of Incyte International | Other Derivative Acquisition | +13,498 | -- |
| 2026-07-22 | Lee Heeson | Executive VP & Head of Incyte International | Other Derivative Acquisition | +15,423 | $116.69 |
| 2026-07-15 | Pablo Cagnoni | President and Head of Research & Development | Other Acquisition | +13,403 | -- |
| 2026-07-15 | Pablo Cagnoni | President and Head of Research & Development | Other Derivative Acquisition | +33,508 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:46:26 · For reference only, not investment advice and not tailored to your situation.